Trials / No Longer Available
No Longer AvailableNCT03850704
Single Patient Use of Selinexor and Dexamethasone for a Patient With Multiple Myeloma
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Masonic Cancer Center, University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This is an individual patient, expanded access protocol using Selinexor and dexamethasone ("Sd") for the treatment of Relapsed, Refractory multiple myeloma in a 64 year old male, "19023-UMN-01" weighing 105.7 kg. 19023-UMN-01 has IgG kappa myeloma that has relapsed after numerous treatments.
Detailed description
Selinexor is an oral, first in class, slowly reversible, potent and Selective Inhibitor of Nuclear Export (SINE) compound that specifically blocks Exportin 1 (XPO1). It is one of the most promising investigational drugs available for this patient with clear risk and benefit assessment favoring potential benefit.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor |
Timeline
- First posted
- 2019-02-22
- Last updated
- 2019-02-22
Source: ClinicalTrials.gov record NCT03850704. Inclusion in this directory is not an endorsement.